Bone marrow-derived CD13(+) cells sustain tumor progression: A potential non-malignant target for anticancer therapy

Non-malignant cells found within neoplastic lesions express alanyl (membrane) aminopeptidase (ANPEP, best known as CD13), and CD13-null mice exhibit limited tumor growth and angiogenesis. We have recently demonstrated that a subset of bone marrow-derived CD11b(+)CD13(+) myeloid cells accumulate with...

Descripción completa

Detalles Bibliográficos
Autores principales: Dondossola, Eleonora, Corti, Angelo, Sidman, Richard L, Arap, Wadih, Pasqualini, Renata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203577/
https://www.ncbi.nlm.nih.gov/pubmed/25339996
http://dx.doi.org/10.4161/onci.27716
_version_ 1782340411819294720
author Dondossola, Eleonora
Corti, Angelo
Sidman, Richard L
Arap, Wadih
Pasqualini, Renata
author_facet Dondossola, Eleonora
Corti, Angelo
Sidman, Richard L
Arap, Wadih
Pasqualini, Renata
author_sort Dondossola, Eleonora
collection PubMed
description Non-malignant cells found within neoplastic lesions express alanyl (membrane) aminopeptidase (ANPEP, best known as CD13), and CD13-null mice exhibit limited tumor growth and angiogenesis. We have recently demonstrated that a subset of bone marrow-derived CD11b(+)CD13(+) myeloid cells accumulate within neoplastic lesions in several murine models of transplantable cancer to promote angiogenesis. If these findings were confirmed in clinical settings, CD11b(+)CD13(+) myeloid cells could become a non-malignant target for the development of novel anticancer regimens.
format Online
Article
Text
id pubmed-4203577
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-42035772015-01-16 Bone marrow-derived CD13(+) cells sustain tumor progression: A potential non-malignant target for anticancer therapy Dondossola, Eleonora Corti, Angelo Sidman, Richard L Arap, Wadih Pasqualini, Renata Oncoimmunology Author's View Non-malignant cells found within neoplastic lesions express alanyl (membrane) aminopeptidase (ANPEP, best known as CD13), and CD13-null mice exhibit limited tumor growth and angiogenesis. We have recently demonstrated that a subset of bone marrow-derived CD11b(+)CD13(+) myeloid cells accumulate within neoplastic lesions in several murine models of transplantable cancer to promote angiogenesis. If these findings were confirmed in clinical settings, CD11b(+)CD13(+) myeloid cells could become a non-malignant target for the development of novel anticancer regimens. Landes Bioscience 2014-01-16 /pmc/articles/PMC4203577/ /pubmed/25339996 http://dx.doi.org/10.4161/onci.27716 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Dondossola, Eleonora
Corti, Angelo
Sidman, Richard L
Arap, Wadih
Pasqualini, Renata
Bone marrow-derived CD13(+) cells sustain tumor progression: A potential non-malignant target for anticancer therapy
title Bone marrow-derived CD13(+) cells sustain tumor progression: A potential non-malignant target for anticancer therapy
title_full Bone marrow-derived CD13(+) cells sustain tumor progression: A potential non-malignant target for anticancer therapy
title_fullStr Bone marrow-derived CD13(+) cells sustain tumor progression: A potential non-malignant target for anticancer therapy
title_full_unstemmed Bone marrow-derived CD13(+) cells sustain tumor progression: A potential non-malignant target for anticancer therapy
title_short Bone marrow-derived CD13(+) cells sustain tumor progression: A potential non-malignant target for anticancer therapy
title_sort bone marrow-derived cd13(+) cells sustain tumor progression: a potential non-malignant target for anticancer therapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203577/
https://www.ncbi.nlm.nih.gov/pubmed/25339996
http://dx.doi.org/10.4161/onci.27716
work_keys_str_mv AT dondossolaeleonora bonemarrowderivedcd13cellssustaintumorprogressionapotentialnonmalignanttargetforanticancertherapy
AT cortiangelo bonemarrowderivedcd13cellssustaintumorprogressionapotentialnonmalignanttargetforanticancertherapy
AT sidmanrichardl bonemarrowderivedcd13cellssustaintumorprogressionapotentialnonmalignanttargetforanticancertherapy
AT arapwadih bonemarrowderivedcd13cellssustaintumorprogressionapotentialnonmalignanttargetforanticancertherapy
AT pasqualinirenata bonemarrowderivedcd13cellssustaintumorprogressionapotentialnonmalignanttargetforanticancertherapy

Ejemplares similares